Keywords: UK, NICE Guidance, Sanofi-Aventis, Multaq,

Draft guidance from UK’s NICE unable to recommend Sanofi-Aventis’ Multaq for atrial fibrillation

Article | 24 December 2009

Print This

The UK’s National Institute for Health and Clinical Excellence (NICE) says it is currently appraising the use of French ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in